EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> DBV Technologies filed a biologics license application for Viaskin Peanut. The submission features data intended to address the FDA’s issues with the original filing. Statement  

> A phase 2b/3 trial of TopiVert Pharma’s treatment for dry eye disease missed its primary endpoints. TopiVert plans to run another study of the drug. Release 

> ObsEva secured a $75 million credit facility with Oxford Finance. The Swiss company will use the money to fund phase 3 trials. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> MorphoSys signaled its intention to file for approval of tafasitamab in Europe. The plan is to complete the submission around the middle of next year. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.